8-K Announcements
4Material company update
May 7, 2026·SEC
Material company update
Apr 16, 2026·SEC
Material company update
Mar 3, 2026·SEC
Prime Medicine, Inc.(PRME)Earnings, Financials & Key Ratios
PRME•NASDAQ
Price updated Jun 19, 2026
AboutPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$5M+55.3%
- EBITDA-$203M-3.4%
- Net Income-$201M-2.7%
- EPS (Diluted)-1.35+18.3%
- Gross Margin-58.05%-158.1%
- EBITDA Margin-4381.82%+33.4%
- Operating Margin-4498.06%+33.7%
- Net Margin-4342.44%+33.9%
- ROE-146.81%-7.3%
PRME Key Insights
Prime Medicine, Inc. (PRME) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 126.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 25.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PRME posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRME Price & Volume
Prime Medicine, Inc. (PRME) stock price & volume — 10-year historical chart
Loading chart...
PRME Growth Metrics
Prime Medicine, Inc. (PRME) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-2.32%
3 Years-
TTM4.89%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1.8%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.47%
Return on Capital
10 Years-75.01%
5 Years-72.72%
3 Years-87.58%
Last Year-73.77%
PRME Recent Earnings
Prime Medicine, Inc. (PRME) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 1/12 qtrs (11%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.28-16.7%
$0.24
Rev
$856,000-63.2%
$2M
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.22+12.0%
$0.25
Rev
$842,000-34.6%
$1M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.32-14.3%
$0.28
Rev
$1M-40.3%
$2M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.41-13.9%
$0.36
Rev
$1M-60.2%
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.28vs $0.24-16.7% | $856,000vs $2M-63.2% |
| Q2 2026 | Mar 3, 2026 | $0.22vs $0.25+12.0% | $842,000vs $1M-34.6% |
| Q4 2025 | Nov 7, 2025 | $0.32vs $0.28-14.3% | $1Mvs $2M-40.3% |
| Q3 2025 | Aug 7, 2025 | $0.41vs $0.36-13.9% | $1Mvs $3M-60.2% |
Based on last 12 quarters of dataView full earnings history →
PRME Peer Comparison
Prime Medicine, Inc. (PRME) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 KRRO | 129.29M | 12.99 | -1.04 | 181.46% | -29.54% | -117.86% | 0.85 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare PRME vs Peers
Prime Medicine, Inc. (PRME) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRME Income Statement
Prime Medicine, Inc. (PRME) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 5.21M | 0 | 0 | 0 | 2.98M | 4.63M | 4.03M |
Revenue Growth % | - | - | -100% | - | - | - | 55.28% | 4.89% |
Cost of Goods Sold | 2.76M | 2.98M | 0 | 0 | 0 | 0 | 7.32M | 47.71M |
COGS % of Revenue | - | 57.2% | - | - | - | - | 158.05% | - |
Gross Profit | -2.76M▲ 0% | 2.23M▲ 180.8% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 2.98M▲ 0% | -2.69M▼ 190.1% | -43.68M▲ 0% |
Gross Margin % | - | 42.8% | - | - | - | 100% | -58.05% | -1082.7% |
Gross Profit Growth % | - | 180.8% | -100% | - | - | - | -190.14% | - |
Operating Expenses | 2.17M | 3.16M | 84.47M | 116.54M | 204.79M | 205.45M | 205.66M | 162.94M |
OpEx % of Revenue | - | 60.69% | - | - | - | 6887.36% | 4440% | - |
Selling, General & Admin | 1.25M | 3.16M | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M | 56.47M |
SG&A % of Revenue | - | 60.69% | - | - | - | 1681.56% | 1130.1% | - |
Research & Development | 920K | 2.98M | 70.55M | 86.72M | 147.91M | 155.29M | 160.64M | 154.18M |
R&D % of Revenue | - | 57.2% | - | - | - | 5205.8% | 3467.96% | - |
Other Operating Expenses | 0 | -2.98M | 0 | 0 | 13.5M | 0 | -7.32M | -3M |
Operating Income | -2.17M▲ 0% | -932K▲ 57.1% | -84.47M▼ 8963.7% | -116.54M▼ 38.0% | -204.79M▼ 75.7% | -202.47M▲ 1.1% | -208.35M▼ 2.9% | -206.61M▲ 0% |
Operating Margin % | - | -17.89% | - | - | - | -6787.36% | -4498.06% | -5121.77% |
Operating Income Growth % | - | 57.09% | -8963.73% | -37.96% | -75.72% | 1.14% | -2.91% | - |
EBITDA | 4.34M | -889K | -83.91M | -114.32M | -200.14M | -196.34M | -202.97M | -199.13M |
EBITDA Margin % | - | -17.06% | - | - | - | -6581.93% | -4381.82% | -4936.42% |
EBITDA Growth % | - | -120.47% | -9338.25% | -36.25% | -75.07% | 1.9% | -3.38% | 0.43% |
D&A (Non-Cash Add-back) | 6.52M | 43K | 568K | 2.22M | 4.65M | 6.13M | 5.38M | 7.48M |
EBIT | -2.52M | -932K | -84.47M | -116.54M | -191.29M | -202.47M | -201.14M | -203.22M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 3.52M | 4.15M | 4.98M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 3.52M | 4.15M | 4.98M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 0 | -611K | -81.38M | -6.22M | 6.38M | 6.58M | 7.21M | 8.24M |
Pretax Income | -2.52M▲ 0% | -1.54M▲ 38.9% | -165.85M▼ 10648.7% | -122.77M▲ 26.0% | -198.41M▼ 61.6% | -195.88M▲ 1.3% | -201.14M▼ 2.7% | -198.37M▲ 0% |
Pretax Margin % | - | -29.62% | - | - | - | -6566.61% | -4342.44% | -4917.55% |
Income Tax | 4K | 1.87M | -486K | -948K | -279K | 0 | 0 | 0 |
Effective Tax Rate % | -0.16% | -121% | 0.29% | 0.77% | 0.14% | 0% | 0% | 0% |
Net Income | -2.53M▲ 0% | -3.41M▼ 34.8% | -165.37M▼ 4749.5% | -121.82M▲ 26.3% | -198.13M▼ 62.6% | -195.88M▲ 1.1% | -201.14M▼ 2.7% | -198.37M▲ 0% |
Net Margin % | - | -65.45% | - | - | - | -6566.61% | -4342.44% | -4917.55% |
Net Income Growth % | - | -34.84% | -4749.47% | 26.33% | -62.64% | 1.14% | -2.69% | 1.8% |
Net Income (Continuing) | -2.53M | -3.41M | -165.37M | -121.82M | -198.13M | -195.88M | -201.14M | -198.37M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.03▲ 0% | -0.05▼ 80.8% | -1.92▼ 3542.6% | -1.46▲ 24.0% | -2.18▼ 49.1% | -1.65▲ 24.2% | -1.35▲ 18.3% | -1.12▲ 0% |
EPS Growth % | - | -80.82% | -3542.61% | 24.04% | -49.09% | 24.17% | 18.26% | 23.47% |
EPS (Basic) | -0.03 | -0.05 | -1.92 | -1.46 | -2.18 | -1.65 | -1.35 | - |
Diluted Shares Outstanding | 95.73M | 95.73M | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M | 177.1M |
Basic Shares Outstanding | 95.73M | 95.73M | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M | 177.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
PRME Balance Sheet
Prime Medicine, Inc. (PRME) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8.7M | 53.4M | 270.58M | 296.62M | 142.98M | 211.89M | 181.29M | 137.89M |
Cash & Short-Term Investments | 8.65M | 53.33M | 269.62M | 293.92M | 121.67M | 190.44M | 177.68M | 135.5M |
Cash Only | 8.65M | 36.98M | 185.42M | 187.62M | 41.57M | 182.48M | 63.03M | 64.11M |
Short-Term Investments | 0 | 16.35M | 84.2M | 106.3M | 80.09M | 7.97M | 114.65M | 71.39M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | 2.71 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 50K | 0 | 0 | 246K | 2.25M | 14.67M | 3.61M | 2.39M |
Total Non-Current Assets | 0 | 1.38M | 31.28M | 63.7M | 50.88M | 85.62M | 161.44M | 156.84M |
Property, Plant & Equipment | 0 | 596K | 15.68M | 48.55M | 36.6M | 71.56M | 146.75M | 142.15M |
Fixed Asset Turnover | - | 8.74x | - | - | - | 0.04x | 0.03x | 0.03x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.69M |
Other Non-Current Assets | 0 | 785K | 15.6M | 15.14M | 14.28M | 14.06M | 14.69M | 14.69M |
Total Assets | 8.7M▲ 0% | 54.78M▲ 529.9% | 301.86M▲ 451.0% | 360.31M▲ 19.4% | 193.85M▼ 46.2% | 297.51M▲ 53.5% | 342.73M▲ 15.2% | 294.73M▲ 0% |
Asset Turnover | - | 0.10x | - | - | - | 0.01x | 0.01x | 0.01x |
Asset Growth % | - | 529.91% | 451% | 19.37% | -46.2% | 53.47% | 15.2% | 28.14% |
Total Current Liabilities | 7.31M | 19.44M | 57.98M | 26.71M | 56.42M | 37.96M | 37.45M | 36.29M |
Accounts Payable | 0 | 250K | 1.44M | 4.33M | 19.54M | 11.35M | 8.89M | 12.32M |
Days Payables Outstanding | - | 30.62 | - | - | - | - | 443.08 | 70.66 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 8.14M | 8.55M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 7.09M | 7.82M | 30.41M |
Other Current Liabilities | 7.31M | 19.08M | 14.66M | 6.98M | 10.91M | 6.93M | 12.6M | 8.1M |
Current Ratio | 1.19x | 2.75x | 4.67x | 11.10x | 2.53x | 5.58x | 4.84x | 3.80x |
Quick Ratio | 1.19x | 2.75x | 4.67x | 11.10x | 2.53x | 5.58x | 4.84x | 3.80x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -67.94 |
Total Non-Current Liabilities | 0 | 1.87M | 4.31M | 17.33M | 4.36M | 106.4M | 184.42M | 181.74M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 108.29M | 105.97M |
Capital Lease Obligations | 0 | 0 | 3.07M | 17.05M | 4.36M | 37.18M | 0 | 112.48M |
Deferred Tax Liabilities | 0 | 1.87M | 1.24M | 279K | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 6M | 76.13M | 75.78M |
Total Liabilities | 7.31M | 21.31M | 62.3M | 44.04M | 60.78M | 144.36M | 221.87M | 218.03M |
Total Debt | 0 | 0 | 10.41M | 28.75M | 13.63M | 40.79M | 116.43M | 114.51M |
Net Debt | -8.65M | -36.98M | -175.01M | -158.88M | -27.94M | -141.68M | 53.4M | 50.41M |
Debt / Equity | - | - | 0.04x | 0.09x | 0.10x | 0.27x | 0.96x | 1.49x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.58x |
Net Debt / EBITDA | -1.99x | - | - | - | - | - | - | -0.25x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | 1.39M▲ 0% | 33.47M▲ 2309.9% | 239.56M▲ 615.7% | 316.27M▲ 32.0% | 133.07M▼ 57.9% | 153.15M▲ 15.1% | 120.87M▼ 21.1% | 76.7M▲ 0% |
Equity Growth % | - | 2309.94% | 615.66% | 32.02% | -57.92% | 15.09% | -21.08% | -133% |
Book Value per Share | 0.01 | 0.35 | 2.50 | 3.25 | 1.46 | 1.29 | 0.81 | 0.43 |
Total Shareholders' Equity | 1.39M | 33.47M | 239.56M | 316.27M | 133.07M | 153.15M | 120.87M | 76.7M |
Common Stock | 1K | 0 | 0 | 2K | 2K | 2K | 2K | 2K |
Retained Earnings | -2.6M | -6.01M | -171.38M | -293.2M | -491.33M | -687.21M | -888.35M | -937.48M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -27K | -384K | -15K | 1K | 82K | -1K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRME Cash Flow Statement
Prime Medicine, Inc. (PRME) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.33M | -5.54M | -34.08M | -131.83M | -165.41M | -122.86M | -162.56M | -156.42M |
Operating CF Margin % | - | -106.41% | - | - | - | -4118.84% | -3509.59% | - |
Operating CF Growth % | - | -315.59% | -514.75% | -286.79% | -25.48% | 25.72% | -32.31% | -343.01% |
Net Income | -2.53M | -3.41M | -165.37M | -121.82M | -198.13M | -195.88M | -201.14M | -198.37M |
Depreciation & Amortization | 0 | 43K | 568K | 2.22M | 4.65M | 6.13M | 5.38M | 5.7M |
Stock-Based Compensation | 0 | 391K | 1.75M | 6.46M | 13.91M | 26.07M | 29.27M | 23.59M |
Deferred Taxes | 0 | 1.87M | -624K | -964K | -279K | 0 | 0 | 0 |
Other Non-Cash Items | 703K | -4.6M | 98.42M | 17.68M | 11.79M | 9.74M | 9.27M | 12.85M |
Working Capital Changes | 492K | 164K | 31.18M | -35.4M | 2.65M | 31.08M | -5.34M | -187K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 250K | 1.19M | 2.46M | 9.14M | -5.26M | 996K | 2.66M |
Cash from Investing | 0 | -1.06M | -73.63M | -47.1M | 18.71M | 68.46M | -108.76M | -17.63M |
Capital Expenditures | 0 | -639K | -4.15M | -16.09M | -8.72M | -7.29M | -4.53M | -2.32M |
CapEx % of Revenue | - | 12.26% | - | - | - | 244.52% | 97.82% | 57.59% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | -423K | -496K | -665K | -170K | 1M | 0 | 0 |
Cash from Financing | 9.98M | 34.93M | 269.28M | 181.49M | 655K | 195.88M | 151.51M | 145.91M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6M |
Equity Issued (Net) | 9.98M | 34.95M | 270.36M | 185.32M | 655K | 170.14M | 139.51M | 393K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -20K | -1.09M | -3.82M | 0 | 25.74M | 12M | 151.51M |
Net Change in Cash | 0▲ 0% | 28.33M▲ 0% | 161.57M▲ 470.4% | 2.57M▼ 98.4% | -146.05M▼ 5780.5% | 141.47M▲ 196.9% | -119.81M▼ 184.7% | -28.14M▲ 0% |
Free Cash Flow | -1.33M▲ 0% | -6.18M▼ 363.5% | -38.23M▼ 518.3% | -147.92M▼ 286.9% | -174.14M▼ 17.7% | -130.16M▲ 25.3% | -167.09M▼ 28.4% | -158.74M▲ 0% |
FCF Margin % | - | -118.68% | - | - | - | -4363.36% | -3607.4% | -3935.05% |
FCF Growth % | - | -363.49% | -518.34% | -286.91% | -17.72% | 25.25% | -28.38% | -42.49% |
FCF per Share | -0.01 | -0.06 | -0.40 | -1.52 | -1.91 | -1.10 | -1.12 | -0.90 |
FCF Conversion (FCF/Net Income) | 0.53x | 1.63x | 0.21x | 1.08x | 0.83x | 0.63x | 0.81x | 0.80x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 141K | 0 | 0 | 0 | 0 |
PRME Key Ratios
Prime Medicine, Inc. (PRME) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -19.56% | -121.13% | -43.83% | -88.19% | -136.88% | -146.81% | -188.82% |
Return on Invested Capital (ROIC) | - | -207.57% | -78.77% | -117.01% | -260.47% | -168.27% | -97.35% |
Gross Margin | 42.8% | - | - | - | 100% | -58.05% | -1082.7% |
Net Margin | -65.45% | - | - | - | -6566.61% | -4342.44% | -4917.55% |
Debt / Equity | - | 0.04x | 0.09x | 0.10x | 0.27x | 0.96x | 1.49x |
FCF Conversion | 1.63x | 0.21x | 1.08x | 0.83x | 0.63x | 0.81x | 0.80x |
Revenue Growth | - | -100% | - | - | - | 55.28% | 4.89% |
Related:PRME Dividend History·PRME Revenue History·PRME Price History·PRME P/E History·PRME Financial Ratios·PRME Institutional Holders
PRME SEC Filings & Documents
Prime Medicine, Inc. (PRME) SEC filings — annual & quarterly reports (10-K, 10-Q)
PRME Frequently Asked Questions
Prime Medicine, Inc. (PRME) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Prime Medicine, Inc. (PRME) reported $4.0M in revenue for fiscal year 2025.
Prime Medicine, Inc. (PRME) grew revenue by 55.3% over the past year. This is strong growth.
Prime Medicine, Inc. (PRME) reported a net loss of $198.4M for fiscal year 2025.
Dividend & Returns
Prime Medicine, Inc. (PRME) has a return on equity (ROE) of -146.8%. Negative ROE indicates the company is unprofitable.
Prime Medicine, Inc. (PRME) had negative free cash flow of $158.7M in fiscal year 2025, likely due to heavy capital investments.